{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:05Z","timestamp":1793126045943,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107649","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:21:08Z","timestamp":1788452468000},"page":"107649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacokinetic properties of the clinical drug candidate PRI-002 with regard to genotype, sex, age, dose-dependence and food effects in mice"],"prefix":"10.1016","volume":"227","author":[{"given":"Luana Cristina","family":"Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2999-4742","authenticated-orcid":false,"given":"Alissa","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0965-3908","authenticated-orcid":false,"given":"Ian","family":"Gering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schemmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6897-4022","authenticated-orcid":false,"given":"Maja","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6725-0755","authenticated-orcid":false,"given":"Antje","family":"Willuweit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kutzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107649_bib0019","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuroscience.2018.05.002","article-title":"Characterization of impaired cerebrovascular structure in APP\/PS1 mouse brains","volume":"385","author":"Ahn","year":"2018","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.ejps.2026.107649_bib0034","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/pharmaceutics12070672","article-title":"Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool","volume":"12","author":"Cheng","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejps.2026.107649_bib0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J. Prev. Alzheimers. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0030","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.ejps.2026.107649_bib0003","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of Aducanumab for Alzheimer Disease-the FDA's perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMa Intern. Med."},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0010","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1038\/s41598-019-41993-6","article-title":"Metabolic resistance of the d-peptide RD2 developed for direct elimination of amyloid-\u03b2 oligomers","volume":"9","author":"Elfgen","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejps.2026.107649_bib0020","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","article-title":"Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease","volume":"33","author":"Erickson","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"5","key":"10.1016\/j.ejps.2026.107649_bib0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1532-5415.1981.tb01766.x","article-title":"Gastric emptying rate in the elderly: implications for drug therapy","volume":"29","author":"Evans","year":"1981","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003088-200038030-00005","article-title":"Age-related changes in protein binding of drugs","volume":"38","author":"Grandison","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0001","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejps.2026.107649_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2017.12.009","article-title":"Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-beta oligomer eliminating all-d-enantiomeric peptide RD2 in mouse plasma","volume":"1073","author":"Hupert","year":"2018","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"5","key":"10.1016\/j.ejps.2026.107649_bib0023","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1021\/acs.molpharmaceut.9b01227","article-title":"Intestinal permeability and oral absorption of selected drugs are reduced in a mouse model of familial Alzheimer\u2019s disease","volume":"17","author":"Jin","year":"2020","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/analytica7010015","article-title":"Development and validation of an UHPLC-ESI-QTOF-MS method according to the ICH M10 guideline for quantification of the clinical drug candidate RD2 in the mouse brain","volume":"7","author":"Jonas","year":"2026","journal-title":"Analytica"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3181\/00379727-75-18083","article-title":"Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins","volume":"75","author":"Kaliss","year":"1950","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.ejps.2026.107649_bib0006","article-title":"A\u03b2 oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo","volume":"3","author":"Kass","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejps.2026.107649_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","article-title":"The mechanisms of pharmacokinetic food-drug interactions \u2013 a perspective from the UNGAP group","volume":"134","author":"Koziolek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2026.107649_bib0012","first-page":"22","article-title":"Large-scale oral treatment study with the four most promising D3-derivatives for the treatment of Alzheimer's disease","author":"Kutzsche","year":"2017","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0013","article-title":"Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: a single and multiple ascending dose phase I study","volume":"6","author":"Kutzsche","year":"2020","journal-title":"Alzheimers. Dement. (N.Y.)"},{"issue":"8","key":"10.1016\/j.ejps.2026.107649_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18443","article-title":"Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - a model of sporadic Alzheimer's disease","volume":"9","author":"Kutzsche","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0014","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1038\/s41467-025-59295-z","article-title":"Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial","volume":"16","author":"Kutzsche","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0031","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","article-title":"Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic \u03b2-amyloid oligomers","volume":"33","author":"Leithold","year":"2016","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0043","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","article-title":"Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic beta-amyloid oligomers","volume":"33","author":"Leithold","year":"2016","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ejps.2026.107649_bib0038","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0023677215615269","article-title":"Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer\u2019s disease","volume":"50","author":"Li","year":"2016","journal-title":"Lab. Anim."},{"issue":"8","key":"10.1016\/j.ejps.2026.107649_bib0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.neuron.2024.01.024","article-title":"Mechanisms of sex differences in Alzheimer\u2019s disease","volume":"112","author":"Lopez-Lee","year":"2024","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107649_bib0036","doi-asserted-by":"crossref","first-page":"eadr8511","DOI":"10.1126\/sciadv.adr8511","article-title":"Investigating gut alterations in Alzheimer\u2019s disease: in-depth analysis with micro- and nano-3D X-ray phase contrast tomography","volume":"11","author":"Palermo","year":"2025","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.ejps.2026.107649_bib0024","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/acs.molpharmaceut.8b00500","article-title":"Altered expression of small intestinal drug transporters and hepatic metabolic enzymes in a mouse model of familial Alzheimer's disease","volume":"15","author":"Pan","year":"2018","journal-title":"Mol. Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2012.01.020","article-title":"The impact of ageing on the barriers to drug delivery","volume":"161","author":"Perrie","year":"2012","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00253003","article-title":"Dose-dependent pharmacokinetics and cancer chemotherapy","volume":"6","author":"Powis","year":"1981","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0029","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.123.001971","article-title":"Preclinical systemic pharmacokinetics, dose proportionality, and Central nervous system distribution of the ATM inhibitor WSD0628, a novel radiosensitizer for the treatment of brain tumors","volume":"390","author":"Rathi","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/00365520310000410","article-title":"Gender differences in gut transit shown with a newly developed radiological procedure","volume":"38","author":"Sadik","year":"2003","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0009","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s12035-018-1209-3","article-title":"Abeta oligomer elimination restores cognition in transgenic Alzheimer's mice with full-blown pathology","volume":"56","author":"Schemmert","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.ejps.2026.107649_bib0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejps.2026.107649_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13654","article-title":"Sexual dimorphism in upper gastrointestinal motility is dependent on duration of fast, time of day, age, and strain of mice","volume":"31","author":"Soni","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0044","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s41999-021-00587-0","article-title":"Sex-related pharmacokinetic differences with aging","volume":"13","author":"Stader","year":"2022","journal-title":"Eur. Geriatr. Med."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107649_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107649_bib0007","doi-asserted-by":"crossref","unstructured":"van Groen, T., et al., The Abeta oligomer eliminating d-enantiomeric peptide RD2 improves cognition without changing plaque pathology. 2017. 7(1): p. 16275.","DOI":"10.1038\/s41598-017-16565-1"},{"issue":"2","key":"10.1016\/j.ejps.2026.107649_bib0042","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.1990.tb03620.x","article-title":"The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein","volume":"29","author":"Veering","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107649_bib0032","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF01061694","article-title":"Influence of food and diet on gastrointestinal drug absorption: a review","volume":"5","author":"Welling","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"3","key":"10.1016\/j.ejps.2026.107649_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0163-7258(89)90019-3","article-title":"Effects of food on drug absorption","volume":"43","author":"Welling","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107649_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106421","article-title":"Evaluation of the 18F-labeled analog of the therapeutic all-d-enantiomeric peptide RD2 for amyloid \u03b2 imaging","volume":"184","author":"Willuweit","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107649_bib0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","article-title":"The blood-brain barrier in Alzheimer's disease","volume":"107","author":"Zenaro","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.ejps.2026.107649_bib0008","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1021\/acschemneuro.9b00458","article-title":"Toward the mode of action of the clinical stage All-d-Enantiomeric peptide RD2 on Abeta42 aggregation","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS. Chem. Neurosci."},{"issue":"11","key":"10.1016\/j.ejps.2026.107649_bib0035","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","article-title":"Intestinal excretion, Intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:55:13Z","timestamp":1793123713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872600223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S092809872600223X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107649","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic properties of the clinical drug candidate PRI-002 with regard to genotype, sex, age, dose-dependence and food effects in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107649"}}